Archive for the ‘research’ Category

Flubendazole With Herxheimer Reactions Followed by a Cure in a Patient With Symptoms Suggestive of Chronic Lyme

https://www.fortunejournals.com/articles/effect-of-flubendazole-with-jarishherxheimer-reactions-followed-by-cure-in-a-patient-with-a-polymorphic-persistent-syndrome-sugges.

Effect of Flubendazole, with Jarish-Herxheimer Reactions Followed by Cure, in A Patient with A Polymorphic Persistent Syndrome Suggestive of Chronic Lyme Disease: A Sign of Parasitic Disease?

Article Information

Alexis Lacout1, Christian Perronne2

1Centre de diagnostic ELSAN, Centre médico-chirurgical 83 avenue Charles de Gaulle 15000 Aurillac, France

2Infectious Diseases, Paris

*Corresponding author: Alexis Lacout. Centre de diagnostic ELSAN, Centre médico-chirurgical 83 avenue Charles de Gaulle 15000 Aurillac, France

Received: 02 February 2023; Accepted: 09 February 2023; Published: 13 March 2024

Citation: Alexis Lacout, Christian Perronne. Effect of Flubendazole, with Jarish-Herxheimer Reactions Followed by Cure, in A Patient with A Polymorphic Persistent Syndrome Suggestive of Chronic Lyme Disease: A Sign of Parasitic Disease. Archives of Microbiology and Immunology. 8 (2024): 96-100.

View / Download PdfShare at Facebook

Abstract

This paper discusses the case of a 40-year-old male patient presenting with a “polymorphic persistent syndrome after a possible tick bite” (SPPT), a syndrome officially recognized by the French High Authority for Health (HAS). Anti-infection protocols were implemented, gradually improving the patient’s clinical condition until complete remission was achieved. Each time flubendazole was taken, it was accompanied by severe symptoms – not suggestive of adverse reactions but of a Jarisch-Herxheimer reaction. Each administration of flubendazole was followed by a period of remission of symptoms.  ________________

**Comment**

Please note study author Dr. Christian Perronne, a long outspoken critic of how Lyme has been handled as well as COVID.  He’s yet another doctor who has been persecuted for this departure from ‘consensus’ based medicine where doctors are expected to check their brains at the door and simply follow illogical and unscientific government dictates.

Flubendazole is a antiparasitic (anthelmintic) agent and a fluorine analogue of mebendazole which is better absorbed when taken with or after a meal.  Used as a dewormer in humans and animals for 40 years, recent studies suggest its potential use as an anticancer agent.  The same can be said of Fenbendazole (Fedben).

I highly recommend viewing Dr. Lee Merrit’s 50 Min video: The Parasite Paradigm.  Parasite egg sacks and cancer look identical under a microscope and German scientists have been saying for decades that cancer is caused by parasites.  Her protocols are found here.

Flubendazole is also available in a slow-release parenteral preparation given subcutaneously or intramuscularly, which allows sustained release over 5 days. The usual dosage is 750 mg/wk for onchocerciasis. It is used to treat hookworm, T. trichiura, and A. lumbricoides. Side effects are vague and mostly abdominal, such as nausea, abdominal pain and rumbling, soft/loose stools, and dyspepsia.  Breathlessness and fatigue have also been reported.

For more on Perronne’s work:

Category:

Activism, Cancer, Lyme, Parasites, research, Treatment

Biologists Map DNA of 47 Strains of Lyme Disease

https://www.lymedisease.org/map-dna-lyme-disease-bacteria/

Biologists map the DNA of 47 strains of Lyme disease

By City University of New York

August 15, 2024

A team led by CUNY Graduate Center biologists has produced a genetic analysis of Lyme disease bacteria that may pave the way for improved diagnosis, treatment, and prevention of the tick-borne ailment.

Weigang Qiu, a professor of biology at the CUNY Graduate Center and Hunter College, and an international team mapped the complete genetic makeup of 47 strains of Lyme disease-related bacteria from around the world. This created a powerful tool for identifying the bacterial strains that infect patients.

More accurate tests and treatments?

Researchers said this could enable more accurate diagnostic tests and treatments tailored to the bacteria causing each patient’s illness.

“By understanding how these bacteria evolve and exchange genetic material, we’re better equipped to monitor their spread and respond to their ability to cause disease in humans,” said Qiu, the corresponding author of the study.

The study was published in mBio, the flagship journal of the American Society for Microbiology.

Researchers said the genetic information uncovered in the study may help scientists develop more effective vaccines against Lyme disease.

Lyme disease is the most common tick-borne illness in North America and Europe, affecting hundreds of thousands of people a year. The disease arises from bacteria belonging to the Borrelia burgdorferi sensu lato group, which infect people through the bite of infected ticks. Symptoms can include fever, headache, fatigue, and a characteristic skin rash. If left untreated, the infection can spread to joints, the heart, and the nervous system, causing more severe complications.

Case numbers are increasing steadily, with 476,000 new cases each year in the United States, and may grow faster with climate change, the authors of the study said.

The research team sequenced the complete genomes of Lyme disease bacteria representing all 23 known species in the group. Most hadn’t been sequenced before the effort. The National Institutes of Health-funded project included many bacteria strains most associated with human infections and species not known to cause disease in humans.

Evolutionary history of Lyme bacteria

By comparing these genomes, the researchers reconstructed the evolutionary history of Lyme disease bacteria, tracing the origins back millions of years. They discovered the bacteria likely originated before the breakup of the ancient supercontinent Pangea, explaining the current worldwide distribution.

The study also disclosed how these bacteria exchange genetic material in and between species. This process, known as recombination, allows the bacteria to rapidly evolve and adapt to new environments. The researchers identified specific hot spots in the bacterial genomes where this genetic exchange occurs most frequently, often involving genes that help the bacteria interact with their tick vectors and animal hosts.

To facilitate ongoing research, the team has developed web-based software tools (BorreliaBase.org) that allow scientists to compare Borrelia genomes and identify determinants of human pathogenicity.

Looking ahead, the researchers said they plan to expand their analysis to include more strains of Lyme disease bacteria, especially from understudied regions. They also aim to investigate the functions of genes unique to disease-causing strains, which could uncover new targets for therapeutic interventions.

As Lyme disease expands its geographic range because of climate change, the research provides valuable tools and insights for combating this rising public health threat.

The study is supported by grants from NIH and an award from the Steven and Alexandra Cohen Foundation.

Click here to read the study.

SOURCE:  CUNY Office of Communications and Marketing

________________

**Comment**

Predictably, the study throws in the globalist talking points of vaccines and climate change, despite there being major disagreements within the scientific community on both issues.

While mapping the strains of borrelia should be good news, nothing will come of this but more lucrative vaccines that will maim and kill many people.  No good tests and no effective treatments will be created.

How do I know?

University research has been hijacked.  NIH, HHS, CDC, and FDA are bought out agencies.  We will get nothing helpful from them.  COVID exposed to all with eyes to see and ears to hear that ‘public health’ isn’t about health at all but  is about power and money.

Patients mean absolutely nothing to these players.

______________

For more:

Category:

Lyme, research, Uncategorized

New Compound Kills Drug-Resistant Bacteria

https://www.theepochtimes.com/health/scientists-develop-new-compound-that-kills-flesh-eating-bacteria-and-other-drug-resistant-bacteria

Scientists Develop New Compound That Kills Flesh-Eating and Other Drug-Resistant Bacteria

The new compound, PS757, may form a new type of antibiotic drug class, researchers hope.

Twenty years ago, professor Fredrik Almqvist, an organic chemistry professor at Umeå University in Sweden, was asked by his collaborating researchers at Washington University in St. Louis (WashU) to design a compound that would prevent urinary tract infections, which are often caused by Gram-negative bacterial infections.

Almqvist’s team created various compounds that were then screened for their effects.

Rather than controlling Gram-negative bacteria adherence, they found some of the compounds were highly effective at killing various Gram-positive bacteria. These included multidrug-resistant strains classified as concerning threats by the U.S. Centers for Disease Control and Prevention (CDC).

The researchers singled out one compound, which they named PS757. Lab testing has shown PS757 to be effective against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), multidrug-resistant Streptococcus pneumoniae, and erythromycin-resistant Streptococcus pyogenes (S. pyogenes), among others.

They further studied the effect of PS757 on S. pyogenes, a potentially flesh-eating bacteria, in animals.  (See link for article)
________________
**Highlights**
  • an animal study shows it may help control the spread of flesh-eating bacteria in rats and aid in recovery.  The study also showed it to be effective against other Gram-positive bacteria.
  • The U.S., China, and the UK has seen resistance to clindamycin.  Linezolid has been a useful alternative.  (I’ve had reports that it’s helped with Lyme/MSIDS)
  • There haven’t been any toxicity studies on PS757 yet.
  • The compound was designed by mimicking a bacterial peptide.
  • The bactericidal effect on wild-type bacteria is only seen with Gram-positives but the scientists are confident they can develop the compound further to affect Gram-negative bacteria.
  • The properties in PS757 make it effective against persister cells, living bacteria that have stopped growing – a particular problem with borrelia, the organism that causes Lyme disease.
  • Without increasing dosage, it can also kill bacteria in biofilms, a protective bacterial community also seen in Lyme/MSIDS patients.
  • So far researchers have not been able to find bacteria resistant to PS757.
  • The compound is now patented and licensed to a company in the hopes of clinical trials and drugs.

Category:

Activism, research, Treatment

Tick Bite Leads to Murder-Suicide

https://www.trialsitenews.com/a/true-crime-as-true-lyme-tick-bite-leads-to-murder-suicide

True Crime as True Lyme: Tick Bite Leads to Murder-Suicide

Investigative Journalist at Trial Site News | In this to change this.
Jul. 24, 2024, 4:30 p.m.

Tortured by Lyme disease, a young man killed his friend and himself. He is not alone.

MARY BETH PFEIFFER

For decades, Lyme disease physicians have seen a small share of late-stage patients with symptoms far beyond the physical ravages of a tick bite. These patients, estimated to be 1 percent of chronic Lyme psychiatric cases, manifest brain disorders so intractable that they become violent, even homicidal.    

Now, a new article in the science journal Heliyon validates these observations and reveals possible mechanisms driving them. It tells the horrific story of a 32-year-old man whose tickborne infection at age 14—one of several—went unrecognized until it was unresponsive to treatment. Failed by short-course antibiotics that mainstream medical guidance swears by, he descended into substance abuse, as many chronic Lyme patients do, to ease his anxiety, depression, and physical pain.

Finally, in the delusional throes of PCP withdrawal, he walked next door, impulsively killed his best friend, stabbed the friend’s father and brother, and turned the knife on himself. He died on a bathroom floor, his mother having tried in vain to stanch two neck wounds.

All of this is a likely outcome of poorly treated Lyme disease under medical protocols that leave even early-treated patients sick—36 percent at six months and 5 percent at fifteen years. While animal studies and a handful of post-mortem reports have illustrated the failure of recommended treatments to quell Lyme disease—using antibiotics in insufficient strength or duration—this study goes further.

For the first time, based on analysis of autopsy samples, it shows both how persisting infection combined with chemical brain changes from substance abuse may have contributed to a disastrous outcome.  (See link for article and study)

________________

**Comment**

It’s stories like these that also make me highly critical of any federal attempt at rectification.

This story is a perfect example of how many go undiagnosed for so long they become recalcitrant.  The picture becomes muddier yet as they seek out ways to simply cope – and in this case turn to harmful drugs which adds a whole other dimension to an already complex picture.

The study thankfully was led by none other than Dr. Robert Bransfield, a literal icon in the world of Lyme and psychiatry.  He’s single-handedly written pretty much all that is known about how Lyme/MSIDS affects the brain.  Even though since 2015 the APA has recommended that evals for mental illness include assessments of ‘locally endemic infectious diseases such as Lyme disease,’ be done, they typically aren’t done.

The study showed that the patient had attached ticks on him at least fifteen times.  At 14 he developed the hallmark summer flu-like illness Lyme is known to cause that his pediatrician considered to be caused by a virus despite an attached tick!  His brain was found to have major inflammation and quinolinic acid – both of which are common in late Lyme disease.  PCP, the illegal drug he took reduces quinolinic acid.

The patient sought but was denied a bed in a substance abuse rehabilitation facility.  PCP withdrawal is known to cause fear, agitation, anxiety, irritability, hallucinations and flashbacks.

For more:

Category:

Activism, Psychological Aspects, research, Ticks

National Committee Creates New Acronym for Lyme: IACI

Lyme IACI, pronounced “Lyme eye-ACK-ee” is the latest fantasy dreamt up by the National Academies of Sciences, Engineering, and Medicine – the congressionally chartered organization that serves as the ‘collective’ scientific national academy of the U.S., which proudly deploys the climate, health, and equity propaganda pushed by globalists.  The sponsors of the organization are none other than:

AstraZeneca
Burroughs Wellcome Fund
Grantham Foundation
JPB Foundation​
McCall MacBain Foundation
Rockefeller Foundation

Are you getting this yet?

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/

Inquiry to the Deputy Director of the Vector-Borne Diseases Division at the CDC

Carl Tuttle
Hudson, NH, United States
Jul 31, 2024

Notice to everyone who has signed this petition:

The following so-called “National Committee” has been established turning persistent Lyme symptoms into a new acronym: Lyme Infection-Associated Chronic Illness (Lyme IACI)

Medscape

‘Doesn’t Fit Anything I Trained for’: National Committee Examines Treatment for Chronic Illness Following Lyme Disease

https://www.medscape.com/viewarticle/doesnt-fit-anything-i-trained-national-committee-examines-2024a1000dru

So now, Chronic Lyme will be swept under the rug for more decades to come despite the mountain of evidence that we have been dealing with an antibiotic resistant/tolerant superbug!

I don’t think this committee is looking to solve (expose) the chronic Lyme epidemic …. it seems more likely this is an opportunity to exploit the chronically infected with money making pharmaceuticals to treat the symptoms of an antibiotic resistant/tolerant superbug.

“Lyme IACI” conveniently sweeps chronic Lyme under the rug.

Please see the email below addressed to Dr. Ben Beard of the CDC with carbon copy to all members of this committee. I ask that everyone demand a response from Beard. You can copy all email addresses below and send a private email or post a comment to the NASEM Committee’s website: https://www8.nationalacademies.org/pa/feedback.aspx?type=project&key=HMD-HSP-23-07

Inquiry to Ben Beard:

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: “cbb0@cdc.gov” <cbb0@cdc.gov>
Cc: “jjohnson@genevausa.org” <jjohnson@genevausa.org>, “theerhisamariee@gmail.com” <theerhisamariee@gmail.com>, “jaucott@jhmi.edu” <jaucott@jhmi.edu>, “cbb0@cdc.gov” <cbb0@cdc.gov>, “jraitt1@stanford.edu” <jraitt1@stanford.edu>, “dclauw@med.umich.edu” <dclauw@med.umich.edu>, “john.leong@tufts.edu” <john.leong@tufts.edu>, “avindra.nath@nih.gov” <avindra.nath@nih.gov>, “charles.chiu@ucsf.edu” <charles.chiu@ucsf.edu>, “elliot.cowan@partnersindiagnostics.com” <elliot.cowan@partnersindiagnostics.com>, “beth.jaworski@nih.hhs.gov” <beth.jaworski@nih.hhs.gov>, “roger@lundquist.org” <roger@lundquist.org>, “rachele.hendricks.sturrup@duke.edu” <rachele.hendricks.sturrup@duke.edu>, “info@lymebiobank.org” <info@lymebiobank.org>, “lorrainejohnson@outlook.com” <lorrainejohnson@outlook.com>, “wendyadams1@gmail.com” <wendyadams1@gmail.com>, “Leith.States@hhs.gov” <Leith.States@hhs.gov>, “tindall.matt@gmail.com” <tindall.matt@gmail.com>, “stacie.hudgens@clinoutsolutions.com” <stacie.hudgens@clinoutsolutions.com>, “raymond_dattwyler@nymc.edu” <raymond_dattwyler@nymc.edu>, “timothy.sellati@globallymealliance.org” <timothy.sellati@globallymealliance.org>, “nklimas@nova.edu” <nklimas@nova.edu>, “kester@genevausa.org” <kester@genevausa.org>, “nicole@nicolemalachowski.com” <nicole@nicolemalachowski.com>, “marcom@genevausa.org” <marcom@genevausa.org>, “stephen.gluckman@pennmedicine.upenn.edu” <stephen.gluckman@pennmedicine.upenn.edu>, “epocratesMedia@athenahealth.com” <epocratesMedia@athenahealth.com>, “epocrates@athenahealth.com” <epocrates@athenahealth.com>
Date: 07/31/2024 7:40 AM EDT
Subject: Inquiry to the Deputy Director of the Vector-Borne Diseases Division at the CDC

Charles B Beard
Deputy Division Director, Division of Vector-Borne Diseases
Centers for Disease Control and Prevention

Dear Dr. Beard,

In 1991 the Lyme disease organism, Borrelia burgdorferi, was grown from the cerebrospinal fluid of patient Vicki Logan at the Centers for Disease Control in Fort Collins, Colorado despite prior treatment with intravenous antibiotics. The patient died when the insurer refused additional IV antibiotics. I have attached a copy of Logan’s positive culture report for your review:

Logan CDC Fort Collins Positive CSF Culture Report (Personal Dropbox storage area)
https://www.dropbox.com/scl/fi/agca4ynn9ok2ykgw6484q/Logan-CDC-Fort-Collins-Positive-CSF-Culture-Report.JPG?rlkey=krhiecm1xdmqs6ubhvjxuzzeo&dl=0

In 1995 the following publication identified treatment-resistant neuroborreliosis:
 
European Neurology 1995
Seronegative Chronic Relapsing Neuroborreliosis
https://www.karger.com/Article/Abstract/117104

In 2018 all patients were culture positive even after multiple years on antibiotics so there was no relief from current antimicrobials. Some of these patients had taken as many as eleven different types of antibiotics. Barbour-Stoener-Kelly (BSK) medium was used and is the same complex medium used in the NIH funded Klempner antibiotic trials.

Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease
https://www.mdpi.com/2227-9032/6/2/33

A recently published autopsy study for a young Lyme patient who committed suicide identifies chronic Lyme disease in the patient’s brain which was responsible for his neurological symptoms.

Concurrent Infection of the Human Brain with Multiple Borrelia Species
Published in MDPI Nov. 29, 2023
https://www.mdpi.com/1422-0067/24/23/16906

Excerpt:

The diverse strategies used by spirochetes to avoid the host immune system and persist in the host include active immune suppression, induction of immune tolerance, phase and antigenic variation, intracellular seclusion, changing of morphological and physiological state in varying environments, formation of biofilms and persistent forms, and, importantly, incursion into immune-privileged sites such as the brain. Invasion of immune-privileged sites allows the spirochetes to not only escape from the host immune system but can also reduce the efficacy of antibiotic therapy. 

In addition, there are 700 peer reviewed publications identifying persistent infection and more evidence of seronegative disease.

Question:

As Deputy Director of the Vector-Borne Diseases Division at the CDC, why has all the evidence indicating Borrelia as an antibiotic resistant/tolerant superbug been ignored for decades?

A response to this inquiry is requested.

Please hit reply all when responding.

Carl Tuttle
Hudson, NH

_______________

**Comment**

When reading the Medscape article, please notice the following:

The committee will not make recommendations on specific approaches to diagnosis and treatment when it issues a report in early 2025 but will instead present “consensus findings” on treatment for chronic illness associated with Lyme disease, including recommendations for advancing treatment.

There have been only a few randomized controlled trials (RCTs) conducted on what the committee is calling Lyme Infection-Associated Chronic Illness (Lyme IACI) for now, and no National Institutes of Health (NIH)-funded RCTs in the past 20 years or so. It’s an area void of the US Food and Drug Administration-approved therapies, void of any consensus on the off-label use of medications, and without any current standard of care or proven mechanisms and pathophysiology, said John Aucott, MD, director of the Johns Hopkins Medicine Lyme Disease Clinical Research Center, Baltimore, one of the invited speakers at a public meeting held by the NASEM in Washington, DC, in July.”

The best way to look at this illness is not from the silos of infectious disease or the silos of rheumatology; you have to look across disciplines,” Aucott, also associate professor of medicine in the Division of Rheumatology, told the committee. “The story doesn’t fit anything I trained for in my infectious disease fellowship. Even today, I’d posit that PTLD is like an island — it’s still not connected to a lot of the mainstream of medicine.”

COVID showed the world the devastating impact of ‘consensus-based medicine,’ which a report has deemed ‘shocking and immortal.’ In this Communist-type paradigm doctors are told by bureaucrats how to treat, what they can use to treat, and what they can’t use to treat.  Anything outside the lines of this monolith simply aren’t allowed.  Doctors who dare to think for themselves are persecuted and ostracized – with the full weight of the government pressing down upon them –  often times losing their medical license.

This is the world Lyme literate doctors (LLMDs) have lived in for forty years.

The article also regurgitates that only 10-20% go on to suffer with persistent symptoms after treatment, when the actual percentages are approximately 60% as many are not diagnosed or treated until much later – often years later.

Lyme/MSIDS will never fit into RCTs because there are too many variables to fit into a nice four-cornered research box.  Many never test positive on the CDC-2-tiered testing, many never get an EM rash, numerous coinfections are involved, not to mention the fact there are multiple strains of borrelia that testing will not pick up, and symptoms are wildly variable.  No two patients look alike.

Category:

Activism, Lyme, research, Testing, Treatment